Cannara Biotech (LOVE) Q3 2024 earnings summary

Executive summary

• Vertically integrated cannabis producer in Quebec with two large cultivation facilities and 1.6M sq ft of space, producing 33,500 kg annually with potential to scale to 100,000 kg.

• Three flagship brands (Tribal, Nugz, Orchid) drive retail revenue and national market share, with 3.2% share nationally and 11.8% in Quebec as of July 2024.

• Growth driven by expansion into new provinces, new SKUs, and wholesale market sales; strategic investments in sales and marketing underway to support further national expansion.

• Focused on premium quality, disruptive pricing, and innovation through pheno hunting and new genetics, with recent launches like Neon Sunshine and Bubble Up.

• Net income for the nine months ended May 31, 2024 was $0.7 million, down from $2.3 million in the prior year period.

Financial highlights

• Q3 2024 net revenues reached $19.5M, up 22.6% year-over-year, with gross profit of $5.7M and gross margin of 29%.

• Adjusted EBITDA of $2.8M for Q3 2024, marking 13 consecutive positive quarters.

• Net income of $2M and free cash flow of $1.2M in Q3 2024; operating cash flow increased 72% to $4.3M.

• Trailing 12 months: $77M net revenue, $16.4M EBITDA, $5M net income.

• Cash position of $5.5M and working capital of $35.2M at Q3 end.

Outlook and guidance

• Targeting number one market share in Quebec by fiscal 2025, with less than 2% gap to the leader.

• Plans to expand production to 75,000 kg by 2028, with phased activation of additional grow rooms.

• Strategic investments in sales force and infrastructure are expected to drive future returns and market share gains.

• No immediate plans for U.S. or international expansion; Canada remains the core focus until dominance is achieved.

• Management expects existing cash, forecasted cash flows, and undrawn credit facilities to fund operations for at least the next 12 months.